United States - English - NLM (National Library of Medicine)

sola pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10)]. diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8. use in specific populations 8.1 pregnancy pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. teratogenic effects: there are no adequate and well-controlled studies of diclofenac sodium topical solution in pregnant women. diclofenac sodium topical solution should not be used by pregnant women as its safe use has not been adequately de

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential bene ts and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac is indicated: diclofenac sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, preexisting asthma). diclofenac is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings).

Canada - English - Health Canada

teva canada limited - diclofenac sodium - suppository - 100mg - diclofenac sodium 100mg - other nonsteroidal antiimflammatory agents

Canada - English - Health Canada

teva canada limited - diclofenac sodium - suppository - 50mg - diclofenac sodium 50mg - other nonsteroidal antiimflammatory agents

Canada - English - Health Canada

teva canada limited - diclofenac sodium - tablet (enteric-coated) - 50mg - diclofenac sodium 50mg - other nonsteroidal antiimflammatory agents

Canada - English - Health Canada

teva canada limited - diclofenac sodium - tablet (extended-release) - 75mg - diclofenac sodium 75mg - other nonsteroidal antiimflammatory agents

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; maize starch; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; methacrylic acid copolymer; triethyl citrate; purified talc; titanium dioxide; iron oxide yellow - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; maize starch; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; methacrylic acid copolymer; triethyl citrate; purified talc; titanium dioxide; iron oxide yellow - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea